In the population of T2DM patients with HF, mainly in females, the increased circulating levels of adropin seemed to be independent from the NT-proBNP predictor for the favorable modification of hemodynamic performances during the long-term administration of SGLT2 inhibitor dapagliflosin. The gene discussed is SLC5A2; the disease is hydrops fetalis.